Intravenous Immunomodulatory Nanoparticles Prevent Secondary Damage after Traumatic Brain Injury.

ABSTRACT: After traumatic brain injury (TBI), monocyte/macrophage infiltration is a key early step in the development of an inflammatory cascade that leads to substantial secondary damage. Intravenous (IV) immunomodulatory nanoparticle (IMP) administration after TBI limits inflammatory cell infiltration and reduces both behavioral decline and lesion size without any noticeable toxicity. Here we show that there is a dose-response relationship between the amount of IMP administered and tissue damage which plateaus at a well-tolerated dose. There is a therapeutic window of efficacy for IMP administration of at least 6 h after injury with some benefit observed when treatment was delayed for 12 h after injury. Single cell RNA sequencing demonstrated substantial changes in gene expression after TBI in bot

SUBMITTER: Bertossi R 

PROVIDER: S-EPMC11971540 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature